Fatigue in ANCA-associated vasculitis (AAV) and systemic sclerosis (SSc): similarities with Myalgic encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A critical review of the literature

References

• Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003 May;2(3):119–125.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Kostov B, et al. Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. Autoimmun Rev. 2015 Aug;14(8):670–679.
   PubMed Web of Science ®Google Scholar
• Bairkdar M, Rossides M, Westerlind H, et al. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford). 2021 Jul 1;60(7):3121–3133.
   PubMed Web of Science ®Google Scholar
• Berti A, Dejaco C. Update on the epidemiology, risk factors, and outcomes of systemic vasculitides. Best Pract Res Clin Rheumatol. 2018 Apr;32(2):271–294.
   PubMed Web of Science ®Google Scholar
• Hellmich B, Lamprecht P, Spearpoint P, et al. New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. Rheumatology (Oxford). 2021 Oct 2;60(10):4868–4873.
   PubMed Web of Science ®Google Scholar
• Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev. 2003 Jun;2(4):181–191.
   PubMed Web of Science ®Google Scholar
• Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020 Aug 27;6(1):71.
   PubMed Web of Science ®Google Scholar
• Osman MS, Tervaert JWC. Anti-neutrophil cytoplasmic antibodies (ANCA) as disease activity biomarkers in a “personalized medicine approach” in ANCA-associated vasculitis. Curr Rheumatol Rep. 2019 Dec 26; 21(12):76.
   PubMed Web of Science ®Google Scholar
• Mehra S, Walker J, Patterson K, et al. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013 Jan;12(3):340–354.
   PubMed Web of Science ®Google Scholar
• Osman M, Redmond D, Tervaert JWC. Comment on: ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies. Rheumatology (Oxford). 2021 Nov 3; 60(11):e407–e9.
   PubMed Web of Science ®Google Scholar
• AARDA. Profound, debilitating fatigue found to be a major issue for autoimmune disease patients in new national survey. 2015. [cited 2021 Aug]. Available from: https://www.aarda.org/fatigue-survey-results-released/
   Google Scholar
• Druce KL, Bhattacharya Y, Jones GT, et al. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British society for rheumatology biologics register for rheumatoid arthritis. Rheumatology (Oxford). 2016 Oct;55(10):1786–1790.
   PubMed Web of Science ®Google Scholar
• Pollard LC, Choy EH, Gonzalez J, et al. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford). 2006 Jul;45(7):885–889.
   PubMed Web of Science ®Google Scholar
• Tench CM, McCurdie I, White PD, et al. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford). 2000 Nov;39(11):1249–1254.
   PubMed Web of Science ®Google Scholar
• Wang B, Gladman DD, Urowitz MB. Fatigue in lupus is not correlated with disease activity. J Rheumatol. 1998 May;25(5):892–895.
   PubMed Web of Science ®Google Scholar
• Ahn GE, Ramsey-Goldman R. Fatigue in systemic lupus erythematosus. Int J Clin Rheumtol. 2012 Apr 1; 7(2):217–227.
   PubMedGoogle Scholar
• Dey M, Parodis I, Nikiphorou E. Fatigue in systemic lupus erythamatosus and rheumatoid arthritis: a comparison of mechanisms, measures and management. J Clin Med. 2021;10(16):3566.
   PubMed Web of Science ®Google Scholar
• Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry. 2003 Feb;160(2):221–236.
   PubMed Web of Science ®Google Scholar
• Pawlikowska T, Chalder T, Hirsch SR, et al. Population based study of fatigue and psychological distress. BMJ. 1994 Mar 19;308(6931):763–766.
   PubMed Web of Science ®Google Scholar
• Bested AC, Marshall LM. Review of myalgic encephalomyelitis/chronic fatigue syndrome: an evidence-based approach to diagnosis and management by clinicians. Rev Environ Health. 2015;30(4):223–249.
   PubMed Web of Science ®Google Scholar
• Komaroff AL. Advances in understanding the pathophysiology of chronic fatigue syndrome. JAMA. 2019 Aug 13; 322(6):499–500.
   PubMed Web of Science ®Google Scholar
• Bateman L, Bested AC, Bonilla HF, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: essentials of diagnosis and management. Mayo Clin Proc. 2021 Nov;96(11):2861–2878.
   PubMed Web of Science ®Google Scholar
• Cortes Rivera M, Mastronardi C, Silva-Aldana CT, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics (Basel). 2019 Aug 7;9(3). 10.3390/diagnostics9030091.
   PubMedGoogle Scholar
• Louati K, Berenbaum F. Fatigue in chronic inflammation - a link to pain pathways. Arthritis Res Ther. 2015 Oct 5;17(1):254.
   PubMedGoogle Scholar
• Montoya JG, Holmes TH, Anderson JN, et al. Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):E7150–E8.
   PubMed Web of Science ®Google Scholar
• Davies K, Dures E, Ng WF. Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research. Nat Rev Rheumatol. 2021 Nov;17(11):651–664.
   PubMed Web of Science ®Google Scholar
• Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med (Lausanne). 2020;7:606824.
   PubMed Web of Science ®Google Scholar
• Congress.Gov. H.R.2754 - COVID–19 long haulers act. 2021. [cited 2022 Jun]. Available from: https://www.congress.gov/bill/117th-congress/house-bill/2754?r=5&s=1
   Google Scholar
• NoListedAuthors. A new clinical entity? Lancet. 1956 May 26;270(6926):789–790.
   PubMedGoogle Scholar
• Hewlett S, Cockshott Z, Byron M, et al. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum. 2005 Oct 15;53(5):697–702.
   PubMedGoogle Scholar
• Sapra A, Bhandari P. Chronic fatigue syndrome. Treasure Island (FL): StatPearls; 2021.
   Google Scholar
• Deale A, Wessely S. Patients’ perceptions of medical care in chronic fatigue syndrome. Soc Sci Med. 2001 Jun;52(12):1859–1864.
   PubMed Web of Science ®Google Scholar
• Carruthers BM, Jain AK, De Meirleir KL, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chron Fatigue Syndr. 2003;11(1):7–115.
   Google Scholar
• Jason LA, McManimen S, Sunnquist M, et al. Examining the institute of medicine’s recommendations regarding chronic fatigue syndrome: clinical versus research criteria. J Neurol Psychol. 2015(Suppl 2) .
   Google Scholar
• Torres-Harding S, Sorenson M, Jason LA, et al. Evidence for T-helper 2 shift and association with illness parameters in chronic fatigue syndrome (CFS). Bull IACFS ME. 2008 Fall;16(3):19–33.
   PubMedGoogle Scholar
• Skowera A, Cleare A, Blair D, et al. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol. 2004 Feb;135(2):294–302.
   PubMed Web of Science ®Google Scholar
• O’Reilly S, Hugle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford). 2012 Sep;51(9):1540–1549.
   PubMed Web of Science ®Google Scholar
• Abdulahad WH, Lamprecht P, Kallenberg CG. T-helper cells as new players in ANCA-associated vasculitides. Arthritis Res Ther. 2011 Aug 23; 13(4):236.
   PubMed Web of Science ®Google Scholar
• Wilde B, Thewissen M, Damoiseaux J, et al. T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells? Arthritis Res Ther. 2010;12(1):204.
   PubMed Web of Science ®Google Scholar
• Fletcher MA, Zeng XR, Maher K, et al. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. Plos One. 2010 May 25;5(5):e10817.
   PubMed Web of Science ®Google Scholar
• Brenu EW, van Driel ML, Staines DR, et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2011 May 28;9(1):81.
   PubMedGoogle Scholar
• Eaton-Fitch N, du Preez S, Cabanas H, et al. A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome. Syst Rev. 2019 Nov 14;8(1):279.
   PubMed Web of Science ®Google Scholar
• Brenu EW, Hardcastle SL, Atkinson GM, et al. Natural killer cells in patients with severe chronic fatigue syndrome. Auto Immun Highlights. 2013 Dec;4(3):69–80.
   PubMedGoogle Scholar
• Strayer D, Scott V, Carter S. Low NK cell activity in chronic fatigue syndrome (CFS) and relationship to symptom severity. J Clin Cell Immunol. 2015;6:1–9.
   Google Scholar
• van Eeden C, Khan L, Osman MS, et al. Natural killer cell dysfunction and its role in COVID-19. Int J Mol Sci. 2020;21(17):6351.
   PubMed Web of Science ®Google Scholar
• Fuchs S, Scheffschick A, Gunnarsson I, et al. Natural killer cells in anti-neutrophil cytoplasmic antibody-associated vasculitis - A review of the literature. Front Immunol. 2021;12:796640.
   PubMed Web of Science ®Google Scholar
• Benyamine A, Magalon J, Sabatier F, et al. Natural killer cells exhibit a peculiar phenotypic profile in systemic sclerosis and are potent inducers of endothelial microparticles release. Front Immunol. 2018;9:1665.
   PubMed Web of Science ®Google Scholar
• Puxeddu I, Bongiorni F, Chimenti D, et al. Cell surface expression of activating receptors and co-receptors on peripheral blood NK cells in systemic autoimmune diseases. Scand J Rheumatol. 2012 Aug;41(4):298–304.
   PubMed Web of Science ®Google Scholar
• Nijs J, De Meirleir K. Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome. Vivo. 2005 Nov-Dec;19:1013–1021.
   PubMed Web of Science ®Google Scholar
• Suhadolnik RJ, Peterson DL, O’Brien K, et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res. 1997 Jul;17(7):377–385.
   PubMed Web of Science ®Google Scholar
• Guenther S, Loebel M, Mooslechner AA, et al. Frequent IgG subclass and mannose binding lectin deficiency in patients with chronic fatigue syndrome. Hum Immunol. 2015 Oct;76(10):729–735.
   PubMed Web of Science ®Google Scholar
• Peterson PK, Shepard J, Macres M, et al. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med. 1990 Nov;89(5):554–560.
   PubMed Web of Science ®Google Scholar
• Wakefield D, Lloyd A, Brockman A. Immunoglobulin subclass abnormalities in patients with chronic fatigue syndrome. Pediatr Infect Dis J. 1990 Aug;9(Supplement):S50–3.
   PubMedGoogle Scholar
• Brouwer E, Tervaert JW, Horst G, et al. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener’s granulomatosis and clinically related disorders. Clin Exp Immunol. 1991 Mar;83(3):379–386.
   PubMed Web of Science ®Google Scholar
• Holland M, Hewins P, Goodall M, et al. Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener’s granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol. 2004 Oct;138(1):183–192.
   PubMed Web of Science ®Google Scholar
• Ma Y, Chen L, Xu Y, et al. Clinical and pathological features of patients with antineutrophil cytoplasmic antibody-associated vasculitides concomitant with IgG4-related disease. Int J Rheum Dis. 2019 Dec;22(12):2143–2150.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li P, Wu D, et al. Serum IgG subclasses in autoimmune diseases. Medicine (Baltimore). 2015 Jan;94(2):e387.
   PubMed Web of Science ®Google Scholar
• Barahona-Correa JE, De la Hoz A, Lopez MJ, et al. Infections and systemic sclerosis: an emerging challenge. Rev Colome Reumatol. 2020;27:62–84.
   Google Scholar
• Tieu J, Smith RM, Gopaluni S, et al. Rituximab associated hypogammaglobulinemia in autoimmune disease. Front Immunol. 2021;12:671503.
   PubMed Web of Science ®Google Scholar
• Loebel M, Grabowski P, Heidecke H, et al. Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun. 2016 Feb;52:32–39.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Ouchi Y, Nakatsuka D, et al. Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor. Plos One. 2012;7(12):e51515.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Kuratsune H, Hidaka Y, et al. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med. 2003 Aug;12(2):225–230.
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Loebel M, Freitag H, et al. Immunoadsorption to remove ss2 adrenergic receptor antibodies in chronic fatigue syndrome CFS/ME. Plos One. 2018;13(3):e0193672.
   PubMed Web of Science ®Google Scholar
• Sotzny F, Blanco J, Capelli E, et al. Myalgic encephalomyelitis/chronic fatigue syndrome - Evidence for an autoimmune disease. Autoimmun Rev. 2018 Jun;17(6):601–609.
   PubMed Web of Science ®Google Scholar
• Hokama Y, Campora CE, Hara C, et al. Anticardiolipin antibodies in the sera of patients with diagnosed chronic fatigue syndrome. J Clin Lab Anal. 2009;23(4):210–212.
   PubMed Web of Science ®Google Scholar
• Hokama Y, Empey-Campora C, Hara C, et al. Acute phase phospholipids related to the cardiolipin of mitochondria in the sera of patients with chronic fatigue syndrome (CFS), chronic Ciguatera fish poisoning (CCFP), and other diseases attributed to chemicals, Gulf War, and marine toxins. J Clin Lab Anal. 2008;22(2):99–105.
   PubMed Web of Science ®Google Scholar
• Cabral-Marques O, Riemekasten G. Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases. Nat Rev Rheumatol. 2017 Nov;13(11):648–656.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wen Q, Qiu Y, et al. Clinical and pathological characteristics of ANA/anti-dsDNA positive patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. Rheumatol Int. 2021 Feb;41(2):455–462.
   PubMed Web of Science ®Google Scholar
• Didier K, Giusti D, Le Jan S, et al. Neutrophil extracellular traps generation relates with early stage and vascular complications in systemic sclerosis. J Clin Med. 2020 Jul 7;9(7):2136.
   Web of Science ®Google Scholar
• Brenu EW, Staines DR, Baskurt OK, et al. Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med. 2010 Jan 11;8(1):1.
   PubMedGoogle Scholar
• Ablashi DV. Viral studies of chronic fatigue syndrome. Clin Infect Dis. 1994 Jan;18 Suppl 1(Supplement_1):S130–3.
   PubMedGoogle Scholar
• Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006 Sep 16;333(7568):575.
   PubMed Web of Science ®Google Scholar
• Rasa S, Nora-Krukle Z, Henning N, et al. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med. 2018 Oct 1;16(1):268.
   PubMedGoogle Scholar
• O’Neal AJ, Hanson MR. The enterovirus theory of disease etiology in myalgic encephalomyelitis/chronic fatigue syndrome: a critical review. Front Med (Lausanne). 2021;8:688486.
   PubMed Web of Science ®Google Scholar
• Komaroff AL, Lipkin WI. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol Med. 2021 Sep;27(9):895–906.
   PubMed Web of Science ®Google Scholar
• Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClin Med. 2021 Aug;38:101019.
   PubMedGoogle Scholar
• Naviaux RK, Naviaux JC, Li K, et al. Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5472–80.
   PubMed Web of Science ®Google Scholar
• Fielenbach N, Antebi AC. C. elegans dauer formation and the molecular basis of plasticity. Genes Dev. 2008 Aug 15; 22(16):2149–2165.
   PubMed Web of Science ®Google Scholar
• Holden S, Maksoud R, Eaton-Fitch N, et al. A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease. J Transl Med. 2020 Jul 29;18(1):290.
   PubMed Web of Science ®Google Scholar
• Kennedy G, Spence VA, McLaren M, et al. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med. 2005 Sep 1;39(5):584–589.
   PubMed Web of Science ®Google Scholar
• Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis. 2014 Mar;29(1):19–36.
   PubMed Web of Science ®Google Scholar
• Jastroch M, Divakaruni AS, Mookerjee S, et al. Mitochondrial proton and electron leaks. Essays Biochem. 2010;47:53–67.
   PubMed Web of Science ®Google Scholar
• Missailidis D, Annesley SJ, Allan CY, et al. An isolated complex V inefficiency and dysregulated mitochondrial function in immortalized lymphocytes from ME/CFS patients. Int J Mol Sci. 2020 Feb 6;21(3):1074.
   Web of Science ®Google Scholar
• Tomas C, Brown A, Strassheim V, et al. Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. Plos One. 2017;12(10):e0186802.
   PubMed Web of Science ®Google Scholar
• Castro-Marrero J, Cordero MD, Saez-Francas N, et al. Could mitochondrial dysfunction be a differentiating marker between chronic fatigue syndrome and fibromyalgia? Antioxid Redox Signal. 2013 Nov 20;19(15):1855–1860.
   PubMed Web of Science ®Google Scholar
• Maes M, Mihaylova I, Kubera M, et al. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett. 2009;30(4):470–476.
   PubMed Web of Science ®Google Scholar
• Abdulle AE, Diercks GFH, Feelisch M, et al. The role of oxidative stress in the development of systemic sclerosis related vasculopathy. Front Physiol. 2018;9:1177.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang D, Hu D, et al. The role of mitochondria in NLRP3 inflammasome activation. Mol Immunol. 2018 Nov;103:115–124.
   PubMed Web of Science ®Google Scholar
• Faas MM, de Vos P. Mitochondrial function in immune cells in health and disease. Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1; 1866(10):165845.
   PubMed Web of Science ®Google Scholar
• Angajala A, Lim S, Phillips JB, et al. Diverse roles of mitochondria in immune responses: novel insights into immuno-metabolism. Front Immunol. 2018;9:1605.
   PubMed Web of Science ®Google Scholar
• Shimojima Y, Kishida D, Ichikawa T, et al. Oxidative stress promotes instability of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis. Front Immunol. 2021;12:789740.
   PubMed Web of Science ®Google Scholar
• Doridot L, Jeljeli M, Chene C, et al. Implication of oxidative stress in the pathogenesis of systemic sclerosis via inflammation, autoimmunity and fibrosis. Redox Biol. 2019 Jul;25:101122.
   PubMed Web of Science ®Google Scholar
• Rutgers A, Heeringa P, Tervaert JW. The role of myeloperoxidase in the pathogenesis of systemic vasculitis. Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S55–63.
   PubMed Web of Science ®Google Scholar
• Harper L, Nuttall SL, Martin U, et al. Adjuvant treatment of patients with antineutrophil cytoplasmic antibody-associated vasculitis with vitamins E and C reduces superoxide production by neutrophils. Rheumatology (Oxford). 2002 Mar;41(3):274–278.
   PubMed Web of Science ®Google Scholar
• Slot MC, Theunissen R, van Paassen P, et al. Anti-oxidized low-density lipoprotein antibodies in myeloperoxidase-positive vasculitis patients preferentially recognize hypochlorite-modified low density lipoproteins. Clin Exp Immunol. 2007 Aug;149(2):257–264.
   PubMed Web of Science ®Google Scholar
• Fuite J, Vernon SD, Broderick G. Neuroendocrine and immune network re-modeling in chronic fatigue syndrome: an exploratory analysis. Genomics. 2008 Dec;92(6):393–399.
   PubMed Web of Science ®Google Scholar
• Torres-Harding S, Sorenson M, Jason L, et al. The associations between basal salivary cortisol and illness symptomatology in chronic fatigue syndrome. J Appl Biobehav Res. 2008 Jan 1;13(3):157–180.
   PubMedGoogle Scholar
• Parker AJ, Wessely S, Cleare AJ. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med. 2001 Nov;31(8):1331–1345.
   PubMed Web of Science ®Google Scholar
• Spies CM, Straub RH, Cutolo M, et al. Circadian rhythms in rheumatology–a glucocorticoid perspective. Arthritis Res Ther. 2014 Nov 13;16(2):S3.
   PubMedGoogle Scholar
• Broersen LH, Pereira AM, Jorgensen JO, et al. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015 Jun;100(6):2171–2180.
   PubMed Web of Science ®Google Scholar
• Bagnato G, Cordova F, Sciortino D, et al. Association between cortisol levels and pain threshold in systemic sclerosis and major depression. Rheumatol Int. 2018 Mar;38(3):433–441.
   PubMed Web of Science ®Google Scholar
• Vernino S, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 national institutes of health expert consensus meeting - Part 1. Auton Neurosci. 2021 Nov;235:102828.
   PubMed Web of Science ®Google Scholar
• Albright F, Light K, Light A, et al. Evidence for a heritable predisposition to chronic fatigue syndrome. BMC Neurol. 2011 May 27;11(1):62.
   PubMedGoogle Scholar
• Dibble JJ, McGrath SJ, Ponting CP. Genetic risk factors of ME/CFS: a critical review. Hum Mol Genet. 2020 Sep 30; 29(R1):R117–R24.
   PubMed Web of Science ®Google Scholar
• Tukiainen T, Villani AC, Yen A, et al. Landscape of X chromosome inactivation across human tissues. Nature. 2017 Oct 11;550(7675):244–248.
   PubMed Web of Science ®Google Scholar
• Laffont S, Guery JC. Deconstructing the sex bias in allergy and autoimmunity: from sex hormones and beyond. Adv Immunol. 2019;142:35–64.
   PubMed Web of Science ®Google Scholar
• Walsh CM, Zainal NZ, Middleton SJ, et al. A family history study of chronic fatigue syndrome. Psychiatr Genet. 2001 Sep;11(3):123–128.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Herrell R, Ashton S, et al. A twin study of chronic fatigue. Psychosom Med. 2001 Nov-Dec;63(6):936–943.
   PubMed Web of Science ®Google Scholar
• Hickie IB, Bansal AS, Kirk KM, et al. A twin study of the etiology of prolonged fatigue and immune activation. Twin Res. 2001 Apr;4(2):94–102.
   PubMedGoogle Scholar
• Farmer A, Scourfield J, Martin N, et al. Is disabling fatigue in childhood influenced by genes? Psychol Med. 1999 Mar;29(2):279–282.
   PubMed Web of Science ®Google Scholar
• Lande A, Fluge O, Strand EB, et al. Human leukocyte antigen alleles associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Sci Rep. 2020 Mar 24;10(1):5267.
   PubMed Web of Science ®Google Scholar
• Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol. 1995;12(2–4):107–128.
   PubMedGoogle Scholar
• Dahlqvist J, Ekman D, Sennblad B, et al. Identification and functional characterization of a novel susceptibility locus for small vessel vasculitis with MPO-ANCA. Rheumatology (Oxford). 2022;61(8): 3461–3470 .
   PubMed Web of Science ®Google Scholar
• Merkel PA, Xie G, Monach PA, et al. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol. 2017 May;69(5):1054–1066.
   PubMed Web of Science ®Google Scholar
• Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012 Jul 19;367(3):214–223.
   PubMed Web of Science ®Google Scholar
• Hilhorst M, Arndt F, Joseph Kemna M, et al. HLA-DPB1 as a risk factor for relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a cohort study. Arthritis Rheumatol. 2016 Jul;68(7):1721–1730.
   PubMed Web of Science ®Google Scholar
• Wang HY, Cui Z, Pei ZY, et al. Risk HLA class II alleles and amino acid residues in myeloperoxidase-ANCA-associated vasculitis. Kidney Int. 2019 Oct;96(4):1010–1019.
   PubMed Web of Science ®Google Scholar
• Smolenska Z, Zabielska-Kaczorowska M, Wojteczek A, et al. Metabolic pattern of systemic sclerosis: association of changes in plasma concentrations of amino acid-related compounds with disease presentation. Front Mol Biosci. 2020;7:585161.
   PubMed Web of Science ®Google Scholar
• Collatz A, Johnston SC, Staines DR, et al. A systematic review of drug therapies for chronic fatigue syndrome/myalgic encephalomyelitis. Clin Ther. 2016 Jun;38(6):1263–71 e9.
   PubMed Web of Science ®Google Scholar
• Pettegrew JW, Levine J, McClure RJ. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression. Mol Psychiatry. 2000 Nov;5(6):616–632.
   PubMed Web of Science ®Google Scholar
• Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010 Apr;149(1):3–13.
   PubMed Web of Science ®Google Scholar
• Clayton EW. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA. 2015 Mar 17;313:1101–1102.
   PubMed Web of Science ®Google Scholar
• Jason L, Benton M, Torres-Harding S, et al. The impact of energy modulation on physical functioning and fatigue severity among patients with ME/CFS. Patient Educ Couns. 2009 Nov;77(2):237–241.
   PubMed Web of Science ®Google Scholar
• Basta F, Afeltra A, Margiotta DPE. Fatigue in systemic sclerosis: a systematic review. Clin Exp Rheumatol. 2018 Jul-Aug;36(113):150–160.
   PubMedGoogle Scholar
• Assassi S, Leyva AL, Mayes MD, et al., Predictors of fatigue severity in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Plos One. 2011;6(10):e26061.
   PubMed Web of Science ®Google Scholar
• Sandusky SB, McGuire L, Smith MT, et al. Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology (Oxford). 2009 Feb;48(2):165–169.
   PubMed Web of Science ®Google Scholar
• Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008 Dec;58(12):3902–3912.
   PubMed Web of Science ®Google Scholar
• Pokeerbux MR, Giovannelli J, Dauchet L, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther. 2019 Apr 3;21(1):86.
   PubMedGoogle Scholar
• Kim DY, Lee JS, Son CG. Systematic review of primary outcome measurements for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in randomized controlled trials. J Clin Med. 2020;9(11): 3463.
   PubMed Web of Science ®Google Scholar
• Broadbent DE, Cooper PF, FitzGerald P, et al. The cognitive failures questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982 Feb;21(1):1–16.
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CFs3rd, Monk TH, et al. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193–213.
   PubMed Web of Science ®Google Scholar
• Kesikburun B, Koseoglu BF, Dogan A, et al. The effects of respiratory muscle weakness and pulmonary involvement on functional status, fatigue and health related quality of life in patients with systemic sclerosis. Arch Rheumatol. 2015;30(2):116–123.
   Web of Science ®Google Scholar
• Peytrignet S, Denton CP, Lunt M, et al. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European scleroderma observational study. Rheumatology. 2018;57(2):370–381.
   PubMed Web of Science ®Google Scholar
• Cetin SY, Calik BB, Ayan A. Investigation of the effectiveness of Tai Chi exercise program in patients with scleroderma: a randomized controlled study. Complement Ther Clin Pract. 2020;40:101181.
   PubMed Web of Science ®Google Scholar
• Yakut H, Ozalevli S, Birlik AM. Fatigue and its relationship with disease-related factors in patients with systemic sclerosis: a cross-sectional study. Turk J Med Sci. 2021;51(2):530–539.
   PubMed Web of Science ®Google Scholar
• Murphy SL, Kratz AL, Khanna D, et al. Fatigue and its association with social participation, functioning, and quality of life in systemic sclerosis. Arthritis Care Res. 2021;73(3):415–422.
   Web of Science ®Google Scholar
• Santiago TL, Santos E, Duarte AC, et al. Happiness, quality of life and their determinants among people with systemic sclerosis: a structural equation modeling approach. Rheumatology (Oxford, England). 2021;60(10):4717–4727.
   PubMed Web of Science ®Google Scholar
• Sierakowska M, Doroszkiewicz H, Sierakowska J, et al. Factors associated with quality of life in systemic sclerosis: a cross-sectional study. Qual Life Res. 2019;28(12):3347–3354.
   PubMed Web of Science ®Google Scholar
• Justo AC, Guimaraes FS, Ferreira AS, et al. Muscle function in women with systemic sclerosis: association with fatigue and general physical function. Clin Biomech (Bristol, Avon). 2017;47:33–39.
   PubMed Web of Science ®Google Scholar
• Sierakowska M, Krajewska-Kutak E, Sierakowski S, et al. Comparative analysis of educational needs of patients with rheumatic diseases selected based on the polish version of the educational needs assessment tool (Pol-ENAT). Reumatologia. 2016;54:153–160.
   PubMedGoogle Scholar
• Gok K, Erol K, Cengiz G, et al. Comparison of level of fatigue and disease correlates in patients with rheumatoid arthritis and systemic sclerosis. Arch Rheumatol. 2018;33(3):316–321.
   PubMed Web of Science ®Google Scholar
• Murphy SL, Whibley D, Kratz AL, et al. Fatigue predicts future reduced social participation, not reduced physical function or quality of life in people with systemic sclerosis. Journal of Scleroderma and Related Disorders. 2021;6(2):187–193.
   PubMed Web of Science ®Google Scholar
• March C, Huscher D, Preis E, et al. Prevalence, risk factors and assessment of depressive symptoms in patients with systemic sclerosis. Arch Rheumatol. 2019;34(3):253–261.
   PubMed Web of Science ®Google Scholar
• Horsley-Silva JL, Umar SB, Vela MF, et al. The impact of gastroesophageal reflux disease symptoms in scleroderma: effects on sleep quality. Dis Esophagus. 2019;32(5). 10.1093/dote/doy136.
   PubMed Web of Science ®Google Scholar
• Yakut H, Ozalevli S, Aktan R, et al. Effects of supervised exercise program and home exercise program in patients with systemic sclerosis: a randomized controlled trial. Int J Rheum Dis. 2021;24(9):1200–1212.
   PubMed Web of Science ®Google Scholar
• Sierakowska M, Krajewska-Kulak E, Sierakowski S, et al., Pain, fatigue and functional disability are associated with higher educational needs in systemic sclerosis: a cross-sectional study. Rheumatol Int. 2018;38(8):1471–1478.
   PubMed Web of Science ®Google Scholar
• Frech T, Hays RD, Maranian P, et al. Prevalence and correlates of sleep disturbance in systemic sclerosis–results from the UCLA scleroderma quality of life study. Rheumatology (Oxford). 2011 Jul;50(7):1280–1287.
   PubMed Web of Science ®Google Scholar
• Sariyildiz MA, Batmaz I, Budulgan M, et al. Sleep quality in patients with systemic sclerosis: relationship between the clinical variables, depressive symptoms, functional status, and the quality of life. Rheumatol Int. 2013 Aug;33(8):1973–1979.
   PubMed Web of Science ®Google Scholar
• Levis B, Kwakkenbos L, Hudson M, et al. The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian scleroderma research group registry patients. Clin Rheumatol. 2017 Feb;36(2):373–379.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2012 Jan];65(1):1–11.
   Web of Science ®Google Scholar
• Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017 Nov;13(11):683–692.
   PubMed Web of Science ®Google Scholar
• Hilhorst M, van Paassen P, Tervaert JW, et al. Proteinase 3-ANCA vasculitis versus Myeloperoxidase-ANCA Vasculitis. J Am Soc Nephrol. 2015 Oct;26(10):2314–2327.
   PubMed Web of Science ®Google Scholar
• Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011 Mar;70(3):488–494.
   PubMed Web of Science ®Google Scholar
• Hilhorst M, Wilde B, van Paassen P, et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant. 2013 Feb;28(2):373–379.
   PubMed Web of Science ®Google Scholar
• Exley AR, Moots RM, Carruthers D, et al. Short-form 36 in vasculitis. Clin Exp Immunol. 1995;63:101.
   Google Scholar
• Herlyn K, Reinhold-Keller E, Zeidler A, et al. Health-related quality of life in primary systematic vasculitides. Arthritis Rheum. 1998;41(1):122.
   PubMedGoogle Scholar
• Raza K, Wilson A, Carruthers DM, et al. Impaired SF36 in patients with primary systematic necrotizing vasculitis (PSNV): influence of factors besides disease activity and damage. Arthritis Rheam. 1999;42:315.
   Google Scholar
• Gill N, Tervaert JWC, Yacyshyn E. Vasculitis patient journey: a scoping review of patient experiences with vasculitis. Clin Rheumatol. 2021 May;40(5):1697–1708.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Drucker Y, Cotch MF, et al. Wegener’s granulomatosis: patient-reported effects of disease on health, function, and income. Arthritis Rheum. 1998 Dec;41(12):2257–2262.
   PubMedGoogle Scholar
• Boomsma MM, Stegeman CA, Tervaert JW. Comparison of dutch and US patients’ perceptions of the effects of Wegener’s granulomatosis on health, function, income, and interpersonal relationships: comment on the article by Hoffman et al. Arthritis Rheum. 1999 Nov;42(11):2495–2497.
   PubMedGoogle Scholar
• Robson JC, Dawson J, Doll H, et al. Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Ann Rheum Dis. 2018 Aug;77(8):1157–1164.
   PubMed Web of Science ®Google Scholar
• Basu N, Jones GT, Fluck N, et al. Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology (Oxford). 2010 Jul;49(7):1383–1390.
   PubMed Web of Science ®Google Scholar
• Basu N, McClean A, Harper L, et al. Explaining fatigue in ANCA-associated vasculitis. Rheumatology (Oxford). 2013 Sep;52(9):1680–1685.
   PubMed Web of Science ®Google Scholar
• Macfarlane GJ, Jones GT, Swafe L, et al. Alternative population sampling frames produced important differences in estimates of association: a case-control study of vasculitis. J Clin Epidemiol. 2013 Jun;66(6):675–680.
   PubMed Web of Science ®Google Scholar
• Hajj-Ali RA, Wilke WS, Calabrese LH, et al. Pilot study to assess the frequency of fibromyalgia, depression, and sleep disorders in patients with granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res (Hoboken). 2011 Jun;63:827–833.
   PubMed Web of Science ®Google Scholar
• Grayson PC, Amudala NA, McAlear CA, et al. Illness perceptions and fatigue in systemic vasculitis. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1835–1843.
   PubMed Web of Science ®Google Scholar
• Mayor H, Reidy J. The role of pain, perseverative cognition and goal adjustment in vasculitis-associated fatigue. J Health Psychol. 2018 Sep;23(10):1299–1308.
   PubMed Web of Science ®Google Scholar
• Can Sandikci S, Colak S, Omma A, et al. An evaluation of depression, anxiety and fatigue in patients with Behcet’s disease. Int J Rheum Dis. 2019;22(6):974–979.
   PubMed Web of Science ®Google Scholar
• McClean A, Morgan MD, Basu N, et al. Physical fatigue, fitness, and muscle function in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2016;68(9):1332–1339.
   PubMed Web of Science ®Google Scholar
• Koutantji M, Harrold E, Lane SE, et al. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum. 2003 Dec 15;49(6):826–837.
   PubMedGoogle Scholar
• Tomasson G, Farrar JT, Cuthbertson D, et al. Feasibility and construct validation of the patient reported outcomes measurement information system in systemic vasculitis. J Rheumatol. 2019;46(8):928–934.
   PubMed Web of Science ®Google Scholar
• Rimland CA, Quinn KA, Rosenblum JS, et al. Outcome measures in large vessel vasculitis: relationship between patient-, physician-, imaging-, and laboratory-based assessments. Arthritis Care Res (Hoboken). 2020;72(9):1296–1304.
   PubMed Web of Science ®Google Scholar
• Ilhan B, Can M, Alibaz-Oner F, et al. Fatigue in patients with Behcet’s syndrome: relationship with quality of life, depression, anxiety, disability and disease activity. Int J Rheum Dis. 2016;21(12):2139–2145.
   PubMed Web of Science ®Google Scholar
• Basu N, McClean A, Harper L, et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis. 2014 Jan;73(1):207–211.
   PubMed Web of Science ®Google Scholar
• Tuin J, Sanders JS, Buhl BM, et al. Androgen deficiency in male patients diagnosed with ANCA-associated vasculitis: a cause of fatigue and reduced health-related quality of life? Arthritis Res Ther. 2013;15(5):R117.
   PubMed Web of Science ®Google Scholar
• Basu N, Murray AD, Jones GT, et al. Fatigue-related brain white matter changes in granulomatosis with polyangiitis. Rheumatology (Oxford, England). 2013;52(8):1429–1434.
   PubMed Web of Science ®Google Scholar
• Basu N, Murray AD, Jones GT, et al. Neural correlates of fatigue in granulomatosis with polyangiitis: a functional magnetic resonance imaging study. Rheumatology (Oxford). 2014 Nov;53(11):2080–2087.
   PubMed Web of Science ®Google Scholar
• Kim BH, Namkoong K, Kim JJ, et al. Altered resting-state functional connectivity in women with chronic fatigue syndrome. Psychiatry Res. 2015 Dec 30;234(3):292–297.
   PubMed Web of Science ®Google Scholar
• Grayson PC, Amudala NA, McAlear CA, et al. Causal attributions about disease onset and relapse in patients with systemic vasculitis. J Rheumatol. 2014;41(5):923–930.
   PubMed Web of Science ®Google Scholar
• Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15;363(3):211–220.
   PubMed Web of Science ®Google Scholar
• Jones RB, Hiemstra TF, Ballarin J, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019 Mar;78(3):399–405.
   PubMed Web of Science ®Google Scholar
• O’Malley L, Druce KL, Chanouzas D, et al. The longitudinal course of fatigue in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2020;47(4):572–579.
   PubMed Web of Science ®Google Scholar
• Strand V, Dimonaco S, Collinson N, et al. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. Arthritis Res Ther. 2019;21(1):64.
   PubMedGoogle Scholar
• Harper L, Hewitt CA, Litchfield I, et al. Management of fatigue with physical activity and behavioural change support in vasculitis: a feasibility study. Rheumatology. 2021;60(9):4130–4140.
   PubMed Web of Science ®Google Scholar
• Litchfield I, Greenfield S, Harper L, et al. Addressing the transition to a chronic condition: exploring independent adoption of self-management by patients with ANCA-associated vasculitis. Rheumatol Adv Pract. 2021;5:rkab075.
   PubMedGoogle Scholar
• Astley C, Clemente G, Terreri MT, et al. Home-based exercise training in childhood-onset takayasu arteritis: a multicenter, randomized, controlled trial. Front Immunol. 2021;12:705250.
   PubMed Web of Science ®Google Scholar
• Katz P. Causes and consequences of fatigue in rheumatoid arthritis. Curr Opin Rheumatol. 2017 May;29(3):269–276.
   PubMed Web of Science ®Google Scholar
• Zahiri S, Jahani S, Sayadi N, et al. The effects of an educational intervention on fatigue and activities of daily living in patients with systemic lupus erythematosus [Original Article]. Nursing and Midwifery Studies. 2022Jan 1;11:24–30.
   Web of Science ®Google Scholar
• Carandang K, Poole J, Connolly D. Fatigue and activity management education for individuals with systemic sclerosis: adaptation and feasibility study of an intervention for a rare disease. Musculoskeletal Care. 2022 Feb 6. DOI:10.1002/msc.1617
   PubMed Web of Science ®Google Scholar
• Raunsbaek Knudsen L, Lomborg K, Ndosi M, et al. The effectiveness of e-learning in patient education delivered to patients with rheumatoid arthritis: the WebRA study-protocol for a pragmatic randomised controlled trial. BMC Rheumatol. 2021 Dec 20;5(1):57.
   PubMedGoogle Scholar
• Nordlund J, Henry RS, Kwakkenbos L, et al. The scleroderma patient-centered intervention network self-management (SPIN-SELF) program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. Trials. 2021 Nov 27;22(1):856.
   PubMed Web of Science ®Google Scholar
• Kelley GA, Kelley KS, Callahan LF. Aerobic exercise and fatigue in rheumatoid arthritis participants: a meta-analysis using the minimal important difference approach. Arthritis Care Res (Hoboken). 2018 Dec;70(12):1735–1739.
   PubMed Web of Science ®Google Scholar
• Wu ML, Yu KH, Tsai JC. The effectiveness of exercise in adults with systemic lupus erythematosus: a systematic review and meta-analysis to guide evidence-based practice. Worldviews Evid Based Nurs. 2017 Aug;14(4):306–315.
   PubMed Web of Science ®Google Scholar
• Menshikova EV, Ritov VB, Fairfull L, et al. Effects of exercise on mitochondrial content and function in aging human skeletal muscle. J Gerontol A Biol Sci Med Sci. 2006 Jun;61(6):534–540.
   PubMed Web of Science ®Google Scholar
• Llavero F, Alejo LB, Fiuza-Luces C, et al. Exercise training effects on natural killer cells: a preliminary proteomics and systems biology approach. Exerc Immunol Rev. 2021;27:125–141.
   PubMed Web of Science ®Google Scholar
• Paul BD, Lemle MD, Komaroff AL, et al. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci U S A. 2021 Aug 24;118(34). DOI: 10.1073/pnas.2024358118.
   Web of Science ®Google Scholar
• Mancini DM, Brunjes DL, Lala A, et al. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-coronavirus disease. JACC Heart Fail. 2021 Dec;9(12):927–937.
   PubMed Web of Science ®Google Scholar